Journal article
Dysregulation of Tweak and Fn14 in skeletal muscle of spinal muscular atrophy mice
- Abstract:
- Background: Spinal muscular atrophy (SMA) is a childhood neuromuscular disorder caused by depletion of the survival motor neuron (SMN) protein. SMA is characterized by the selective death of spinal cord motor neurons, leading to progressive muscle wasting. Loss of skeletal muscle in SMA is a combination of denervation-induced muscle atrophy and intrinsic muscle pathologies. Elucidation of the pathways involved is essential to identify the key molecules that contribute to and sustain muscle pathology. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)/TNF receptor superfamily member fibroblast growth factor inducible 14 (Fn14) pathway has been shown to play a critical role in the regulation of denervation-induced muscle atrophy as well as muscle proliferation, differentiation and metabolism in adults. However, it is not clear whether this pathway would be important in highly dynamic and developing muscle.Methods: We thus investigated the potential role of the TWEAK/Fn14 pathway in SMA muscle pathology, using the severe Taiwanese Smn-/-;SMN2 and the less severe Smn2B/- SMA mice, which undergo a progressive neuromuscular decline in the first three post-natal weeks. We also used experimental models of denervation and muscle injury in pre-weaned wild type (WT) animals and siRNA-mediated knockdown in C2C12 muscle cells to conduct additional mechanistic investigations.Results: Here, we report significantly dysregulated expression of Tweak, Fn14 and previously proposed downstream effectors during disease progression in skeletal muscle of the two SMA mouse models. In addition, siRNA-mediated Smn knockdown in C2C12 myoblasts suggests a genetic interaction between Smn and the TWEAK/Fn14 pathway. Further analyses of SMA, Tweak-/-and Fn14 -/- mice revealed dysregulated myopathy, myogenesis and glucose metabolism pathways as a common skeletal muscle feature, providing further evidence in support of a relationship between the TWEAK/Fn14 pathway and Smn. Finally, administration of the TWEAK/Fn14 agonist Fc-TWEAK improved disease phenotypes in the two SMA mouse models.Conclusions: Our study provides mechanistic insights into potential molecular players that contribute to muscle pathology in SMA and into likely differential responses of the TWEAK/Fn14 pathway in developing muscle
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 4.0MB, Terms of use)
-
- Publisher copy:
- 10.1186/s13395-022-00301-z
Authors
+ Muscular Dystrophy UK
More from this funder
- Funder identifier:
- 10.13039/100011724
- Grant:
- 18GRO-PS48-0114
+ Academy of Medical Sciences
More from this funder
- Funder identifier:
- 10.13039/501100000691
- Grant:
- SBF006/1162
+ Muscular Dystrophy Ireland/Medical Research CouncilG-HRB
More from this funder
- Grant:
- MRCG-2016-21
- Publisher:
- BioMed Central
- Journal:
- Skeletal Muscle More from this journal
- Volume:
- 12
- Issue:
- 1
- Pages:
- 18-18
- Article number:
- 18
- Publication date:
- 2022-07-28
- DOI:
- EISSN:
-
2044-5040
- ISSN:
-
2044-5040
- Language:
-
English
- Keywords:
- Pubs id:
-
1272708
- Local pid:
-
pubs:1272708
- Source identifiers:
-
W4288084246
- Deposit date:
-
2026-04-27
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2022
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record